Kymera Therapeutics Past Earnings Performance
Past criteria checks 0/6
Key information
-34.7%
Earnings growth rate
62.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 30.8% |
Return on equity | -37.2% |
Net Margin | -187.0% |
Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Kymera KT-333 gets FDA orphan drug status for blood cancer subtype
Sep 15Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces
Aug 15Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M
Aug 09Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Jul 04Kymera Therapeutics: A First Take
Feb 28Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth
Feb 28Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Kymera Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 79 | -147 | 55 | 0 |
30 Sep 23 | 47 | -167 | 52 | 0 |
30 Jun 23 | 52 | -158 | 49 | 0 |
31 Mar 23 | 47 | -159 | 46 | 0 |
31 Dec 22 | 47 | -155 | 44 | 0 |
30 Sep 22 | 46 | -154 | 44 | 0 |
30 Jun 22 | 57 | -139 | 44 | 0 |
31 Mar 22 | 64 | -124 | 41 | 0 |
31 Dec 21 | 73 | -100 | 36 | 0 |
30 Sep 21 | 70 | -79 | 30 | 0 |
30 Jun 21 | 65 | -58 | 26 | 0 |
31 Mar 21 | 49 | -48 | 22 | 0 |
31 Dec 20 | 34 | -55 | 18 | 0 |
30 Sep 20 | 23 | -53 | 16 | 0 |
30 Jun 20 | 9 | -57 | 10 | 0 |
31 Mar 20 | 6 | -52 | 9 | 0 |
31 Dec 19 | 3 | -41 | 8 | 0 |
Quality Earnings: KYMR is currently unprofitable.
Growing Profit Margin: KYMR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KYMR is unprofitable, and losses have increased over the past 5 years at a rate of 34.7% per year.
Accelerating Growth: Unable to compare KYMR's earnings growth over the past year to its 5-year average as it is currently unprofitable